Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer

Biliary cancers (BC) are rare, chemoresistant and are associated with a poor prognosis. Targeting the Akt pathway is of significance in BC. We hypothesized that the allosteric inhibitor MK-2206 will be active in BC. This was a multi-institutional phase II study of MK-2206 given to patients with adva...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Daniel H., Li, Junan, Wei, Lai, Doyle, Austin, Marshall, John L., Schaaf, Larry J., Phelps, Mitch A., Villalona-Calero, Miguel A., Bekaii-Saab, Tanios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894406/
https://www.ncbi.nlm.nih.gov/pubmed/26161813
http://dx.doi.org/10.1038/srep12122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894406/
https://www.ncbi.nlm.nih.gov/pubmed/26161813
http://dx.doi.org/10.1038/srep12122

Ejemplares similares